Risk Evaluation and Mitigation Strategy (REMS)

The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet.

A REMS is a strategy to manage known or potential serious risks associated with a drug product and is required by the FDA to ensure that the benefits of a drug outweigh its risks.

The purpose of the SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet REMS program is to inform healthcare professionals and patients about the safe use conditions and serious risks, including accidental overdose, misuse, and abuse, associated with buprenorphine-containing transmucosal products indicated for the treatment of opioid dependence.

The REMS program includes various materials and processes developed to assist in achieving the following 2 goals:

- Mitigate the risk of accidental overdose, misuse, and abuse
- Inform prescribers, pharmacists, and patients of the serious risks associated with SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet

As a healthcare provider, you can take an active role in implementing REMS, which will help to:

- Ensure the safe and proper use of SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet
- Monitor patients for misuse, abuse, and diversion
- Address any issues that arise and allow you to adjust treatment protocols as necessary

Reference

INDICATION

SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CI) is a prescription medicine indicated for treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CI) is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

SUBUTEX® (buprenorphine) Tablet (CI) is indicated for the treatment of opioid dependence and is preferred for induction. SUBUTEX Tablet should be used as part of a complete treatment plan to include counseling and psychosocial support.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION for SUBOXONE Film
IMPORTANT SAFETY INFORMATION for SUBOXONE Tablet
IMPORTANT SAFETY INFORMATION for SUBUTEX Tablet
Risk Evaluation and Mitigation Strategy (REMS)

The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for SUBOXONE Film, SUBOXONE Tablet, and SUBUTEK Tablet.

A REMS is a strategy to manage known or potential serious risks associated with a drug product and is required by the FDA to ensure that the benefits of a drug outweigh its risks.

The purpose of the SUBOXONE Film, SUBOXONE Tablet, and SUBUTEK Tablet REMS program is to inform healthcare professionals and patients about the safe use conditions and serious risks, including accidental overdose, misuse, and abuse, associated with buprenorphine-containing transmucosal products indicated for the treatment of opioid dependence.

The REMS program includes various materials and processes developed to assist in achieving the following 2 goals:

- Mitigate the risk of accidental overdose, misuse, and abuse
- Inform prescribers, pharmacists, and patients of the serious risks associated with SUBOXONE Film, SUBOXONE Tablet, and SUBUTEK Tablet.

As a healthcare provider, you can take an active role in implementing REMS, which will help to:

- Ensure the safe and proper use of SUBOXONE Film, SUBOXONE Tablet, and SUBUTEK Tablet
- Monitor patients for misuse, abuse, and diversion
- Address any issues that arise and allow you to adjust treatment protocols as necessary

Reference
1. Data on file, Indivior Inc., Richmond, VA.

INDICATION

SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CLP) is a prescription medicine indicated for treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.

Under the Drug Addiction Treatment Act (DATA) codified as 21 U.S.C. 825(q), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CLP) is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 825(q), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

SUBUTEK® (buprenorphine) Tablet (CLP) is indicated for the treatment of opioid dependence and is preferred for induction. SUBUTEK Tablet should be used as part of a complete treatment plan to include counseling and psychosocial support.

Under the Drug Addiction Treatment Act (DATA) codified as 21 U.S.C. 825(q), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION for SUBOXONE Film
IMPORTANT SAFETY INFORMATION for SUBOXONE Tablet
IMPORTANT SAFETY INFORMATION for SUBUTEK Tablet
Risk Evaluation and Mitigation Strategy (REMS)

The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet.

A REMS is a strategy to manage known or potential serious risks associated with a drug product and is required by the FDA to ensure that the benefits of a drug outweigh its risks.

The purpose of the SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet REMS program is to inform healthcare professionals and patients about the safe use conditions and serious risks, including accidental overdose, misuse, and abuse, associated with buprenorphine-containing transmucosal products indicated for the treatment of opioid dependence.

The REMS program includes various materials and processes developed to assist in achieving the following 2 goals:

- Mitigate the risk of accidental overdose, misuse, and abuse
- Inform prescribers, pharmacists, and patients of the serious risks associated with SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet.

As a healthcare provider, you can take an active role in implementing REMS, which will help to:

- Ensure the safe and proper use of SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet
- Monitor patients for misuse, abuse, and diversion
- Address any issues that arise and allow you to adjust treatment protocols as necessary

Reference
1. Data on file, Indivior Inc., Richmond, VA.

INDICATION

SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CII) is a prescription medicine indicated for treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(b), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CII) is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

SUBUTEX® (buprenorphine) Tablet (CII) is indicated for the treatment of opioid dependence and is preferred for induction. SUBUTEX Tablet should be used as part of a complete treatment plan to include counseling and psychosocial support.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION for SUBOXONE Film
IMPORTANT SAFETY INFORMATION for SUBOXONE Tablet
IMPORTANT SAFETY INFORMATION for SUBUTEX Tablet
Risk Evaluation and Mitigation Strategy (REMS)

The Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet.

A REMS is a strategy to manage known or potential serious risks associated with a drug product and is required by the FDA to ensure that the benefits of a drug outweigh its risks.

The purpose of the SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet REMS program is to inform healthcare professionals and patients about the safe use conditions and serious risks, including accidental overdose, misuse, and abuse, associated with buprenorphine-containing transmucosal products indicated for the treatment of opioid dependence.

The REMS program includes various materials and processes developed to assist in achieving the following 2 goals:

- Mitigate the risk of accidental overdose, misuse, and abuse
- Inform prescribers, pharmacists, and patients of the serious risks associated with SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet

As a healthcare provider, you can take an active role in implementing REMS, which will help to:

- Ensure the safe and proper use of SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet
- Monitor patients for misuse, abuse, and diversion
- Address any issues that arise and allow you to adjust treatment protocols as necessary

Reference
1. Data on file, Indivior Inc., Richmond, VA.

INDICATION

SUBOXONE® (buprenorphine and naloxone) Sublingual Film (CLIII) is a prescription medicine indicated for treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 833(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

SUBOXONE® (buprenorphine and naloxone) Sublingual Tablet (CLIII) is indicated for the maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

SUBUTEX® (buprenorphine) Tablet (CLIII) is indicated for the treatment of opioid dependence and is preferred for induction. SUBUTEX Tablet should be used as part of a complete treatment plan to include counseling and psychosocial support.

Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION for SUBOXONE Film
IMPORTANT SAFETY INFORMATION for SUBOXONE Tablet
IMPORTANT SAFETY INFORMATION for SUBUTEX Tablet
Ensuring Appropriate Use

A core element of the REMS is to ensure the benefits of prescribing buprenorphine-containing medications to a patient for treatment of opioid dependence outweigh the risks of accidental overdose, misuse, and abuse. In order to meet the requirements of the REMS, you should take the following measures and document the actions you take to ensure safe use conditions:

- Verify patient meets diagnostic criteria for opioid dependence
- Discuss risks described in the SUBOXONE Film, SUBOXONE Tablet, or SUBUTEX Tablet professional labeling and Medication Guide with patient
- Explain or review conditions of safe storage of medication
- Provide induction doses under appropriate supervision
- Prescribe limited amount of medication at first visit
- Assess and encourage patient to take medication as prescribed
  - Consider film/tablet count/dose reconciliation
- Assess appropriateness of dosage
  - Buprenorphine combined with naloxone is recommended for maintenance:
    - SUBOXONE Film and SUBOXONE Tablet and generic formulations: 16 mg/4 mg is the recommended dose for maintenance
    - SUBUTEX Tablet and generic formulations may be appropriate for maintenance for some patients (e.g., pregnancy, liver disease): 4 mg to 24 mg is the recommended dose range for maintenance
  - Doses higher than this should be an exception
    - The need for higher dose should be carefully evaluated
- Conduct urine drug screens as appropriate to assess use of illicit substances
- Assess participation in professional counseling and support services
- Assess whether benefits of treatment with buprenorphine-containing products outweigh risks associated with SUBOXONE Film, SUBOXONE Tablet, and/or SUBUTEX Tablet
- Assess whether patient is making adequate progress toward treatment goals
  - Consider results of urine drug screens as part of the evidence of the patient complying with the treatment program
  - Consider referral to more intensive forms of treatment for patients not making progress
- Schedule next visit at interval commensurate with patient stability
  - Weekly, or more frequent visits, are recommended for the first month

As part of the SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet REMS program, the prescriber should document safe use conditions and that each patient has received required clinical monitoring using the Appropriate Use Checklist, or by using another method/system (e.g., electronic health record) specific to the prescriber's office practice. This can be retained in the records of each patient. Additional copies of the Appropriate Use Checklist can be obtained online or by calling 1-877-782-9906.
Educating Patients About Treatment

The SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet Medication Guide is a core component of the REMS program. It contains important information about the product, including proper administration, potential adverse events, and other precautions. You should read the medication guide with patients for whom you prescribe SUBOXONE Film, SUBOXONE Tablet, or SUBUTEX Tablet to ensure that they understand the proper use and safety precautions associated with these products. You have received a tear pad with medication guides that you can distribute to patients. If you require additional copies of the medication guide, you can request them through your Clinical Liaison or by calling 1-877-762-6966.

Additionally, tear pads of the medication guides are provided to pharmacies that order and dispense SUBOXONE Film, SUBOXONE Tablet or SUBUTEX Tablet with reminders that they should provide the correct Medication Guide with every prescription.

Messages that need to be communicated to patients about the risks of accidental overdose, misuse, and abuse include the following:

- Patients should be warned that it is extremely dangerous to self-administer non-prescribed benzodiazepines or other central nervous system (CNS) depressants (including alcohol) while taking SUBOXONE Film, SUBOXONE Tablet, or SUBUTEX Tablet. Patients prescribed benzodiazepines or other CNS depressants should be cautioned to use them only as directed by their physician.
- Patients should be advised that SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet contain an opioid that can be a target for people who abuse prescription medications or street drugs. Patients should be cautioned to keep their film or tablets in a safe place, and to protect them from theft.
- Patients should be instructed to keep SUBOXONE Film, SUBOXONE Tablet, or SUBUTEX Tablet in a secure place, out of the sight and reach of children. Accidental or deliberate ingestion by a child may cause respiratory depression that can result in death. Patients should be advised that if a child is exposed to SUBOXONE Film, SUBOXONE Tablet, or SUBUTEX Tablet, medical attention should be sought immediately.
- Patients should be advised never to give SUBOXONE Film, SUBOXONE Tablet, or SUBUTEX Tablet to anyone else, even if he or she has the same signs and symptoms. It may harm them and it is against the law.
- Patients should be instructed to dispose of unused doses of SUBOXONE Film, SUBOXONE Tablet, or SUBUTEX Tablet by flushing the tablets or films down the toilet.

Additional information about safe use conditions and patient monitoring can be found in the Prescriber Brochure and in the warning and precautions sections of the product-specific Prescribing Information.

Further information is available by calling the Indivior Inc. Medical Information Unit at 1-877-SUBOXONE (782-6966) or on suboxone.com.

Reference
1. Data on file, Indivior Inc., Richmond, VA.
Resources For Healthcare Professionals

The materials used to ensure the safe use of SUBOXONE Film, SUBOXONE Tablet, and SUBUTEX Tablet include the Prescribing Information and the Medication Guide, as well as the following:

- REMS Letter to Prescribers
- REMS Letter to Pharmacists
- Appropriate Use Checklist
- Prescriber Brochure
- Pharmacist Brochure
- SUBOXONE Film Prescribing Information
- SUBOXONE Film Medication Guide
- SUBOXONE Tablet Prescribing Information
- SUBOXONE Tablet Medication Guide
- SUBUTEX Tablet Prescribing Information
- SUBUTEX Tablet Medication Guide

The content of these materials is consistent with the Prescribing Information (PI) for the products and includes information on the REMS program and the Elements to Assure Safe Use. They convey the most critical information necessary to ensure the safe use of the products.

Copies of these materials are also available by request through a toll-free information number (1-877-767-8666), and through Clinical Liaisons.